Lauren Koffman, DO
PHOENIX—Like so many things in critical care medicine, treating patients with intracerebral hemorrhage (ICH) is a time-sensitive undertaking. Equally important, however, is deciding which anticoagulant reversal agent to use in these patients, an issue that has been contested since the FDA approved andexanet alfa (Andexxa, AstraZeneca) in 2018. In a session at the 2024 Critical Care Congress, two experts debated the relative merits of andexanet alfa and four-factor